Evidence map›Paper›PMID 40823167›Full record

ArticleJHEP reports : innovation in hepatology2025

Hepatitis D epidemiology and access to diagnostic testing among healthcare providers in Africa: A multi-country survey.

Maria Buti, C Wendy Spearman, Karin Siebelt, Manal El-Sayed

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria ButiLiver Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
C Wendy SpearmanDivision of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.
Karin SiebeltAcademic Medical Education, Utrecht, The Netherlands.
Manal El-SayedAin Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Reliable data on the prevalence of chronic HDV infection in Africa are limited. To address this, a multi-country survey was conducted across Africa to assess healthcare providers' knowledge of HDV prevalence and the availability of diagnostic testing. This was complemented by a literature review of regional HDV prevalence data. Methods: A 12-item web-based questionnaire, created using Google forms, was distributed to all members of SOLDA (the Society on Liver Disease in Africa) and Project ECHO Viral Hepatitis in sub-Saharan Africa (n = 1,210) through African network channels. Survey responses were analyzed using descriptive statistics; all analyses were performed using GraphPad Prism 6. Results: A total of 1,210 surveys were distributed and completed by 608 participants across 43/54 (80%) African countries (44% Eastern, 36% Western, 8% Southern, 6% Northern, and 6% Central regions). Participants from 24/43 (56%) countries were aware of national HDV epidemiological data, mainly in relation to HBsAg carriers (77%), blood donors (23%), patients with chronic liver disease (25%), and those with hepatocellular carcinoma (18%). Anti-HDV antibody testing was available in 30/43 (69%) countries, primarily in clinical studies. The literature review identified 49 studies from 21 countries (mainly in Western and Central Africa), revealing a particularly high HDV prevalence in some countries (Cameroon, Gabon, and Nigeria). In 16 of 22 countries, survey participants' awareness of HDV prevalence was consistent with published data. Conclusions: Healthcare providers' knowledge of HDV prevalence varies across African countries, with 56% aware of national data and 73% aligned with published estimates. While diagnostic testing is available in 69% of countries, it remains limited, is seldom reimbursed, and is not routinely integrated into clinical practice. Impact and implications: This study provides the first continent-wide assessment of healthcare providers' knowledge of HDV prevalence and diagnostic capacity across Africa. The findings reveal significant knowledge gaps - with nearly half of respondents unaware of national HDV data, particularly in Northern Africa - and limited availability of diagnostic testing in clinical practice. While anti-HDV testing is available in 69% of surveyed countries, it is often restricted to research settings, not reimbursed, and rarely integrated into routine care. A complementary literature review confirms that most published data originate from Western and Central Africa, with particularly high HDV prevalence reported in countries such as Cameroon, Gabon, and Nigeria. The study underscores the urgent need for improved HDV surveillance, provider education, and access to diagnostics. Strengthening these areas is essential to inform national hepatitis strategies, guide targeted interventions, and support WHO viral hepatitis elimination goals in the African region.

Indexed as

DiagnosisEpidemiologyHepatitis DSurvey

Identifiers

PMID40823167
PMCPMC12355062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.